Multimodal response prediction to the 177Lu-PSMA radioligand therapy with metastatic prostate cancer

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/50369
• EU PAS number:
  EUPAS50368
• Study ID:
  50369
• Official title and acronym:
  Multimodal response prediction to the 177Lu-PSMA radioligand therapy with metastatic prostate cancer
• DARWIN EU® study:
  No
• Study countries:
  Austria
• Study description:
  The objective of the trial is to investigate the predictability of the therapy response to the 177Lu-PSMA radioligand therapy in men with metastatic prostate cancer using data from routinely acquired functional positron-emission tomography/computed tomography, clinical parameters and cell-free DNA derived from blood samples.
• Study status:
  Planned

Research institutions and networks

Institutions

Medical University of Vienna

Austria

Study timelines

Date when funding contract was signed

Planned: 05/04/2018

Study start date

Planned: 01/02/2023

Date of final study report

Planned: 01/01/2025

Sources of funding

Other

More details on funding

Christian Doppler Society

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable